Thiago Gagliano-Jucá1, M Furkan Burak2, Karol M Pencina1, Zhuoying Li1, Robert R Edwards3, Thomas G Travison4, Shehzad Basaria1. 1. Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 3. Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 4. Program on Aging, Hebrew SeniorLife, Roslindale, Massachusetts.
Abstract
Context: Androgen deprivation therapy (ADT) remains the cornerstone of management of prostate cancer (PCa). Previous studies have shown that men undergoing ADT develop insulin resistance and diabetes, but the mechanisms behind ADT-induced metabolic abnormalities remain unclear. Objective: To evaluate the role of inflammatory cytokines and adipocyte protein-2 (aP2) in ADT-induced metabolic dysfunction. Participants and Interventions: This 6-month prospective cohort study enrolled nondiabetic men with PCa about to undergo ADT (ADT group) and a control group of nondiabetic men who had previously undergone prostatectomy for localized PCa and were in remission (non-ADT group); all participants had normal testosterone at study entry. Fasting blood samples were collected at baseline and at 6, 12, and 24 weeks after initiation of ADT and at the same intervals in the non-ADT group. Glucose, insulin, lipids, inflammatory cytokines, and C-reactive protein were measured. We also measured serum aP2, an adipocyte-secreted protein that promotes hepatic glucose production. Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated. Results: Seventy-three participants formed the analytical sample (33 ADT, 40 non-ADT). HOMA-IR increased in the ADT group (estimated change = 0.25; P = 0.05), but was unchanged in the non-ADT group (0.11; P = 0.342). Serum concentrations of inflammatory cytokines or aP2 did not change significantly. There was a treatment-associated increase in total (16 mg/dL; P < 0.001), high-density lipoprotein (8 mg/dL; P < 0.001), and low-density lipoprotein (7 mg/dL; P = 0.02) cholesterol. Conclusion: ADT-induced metabolic abnormalities were not associated with changes in circulating inflammatory cytokines or aP2 levels.
Context: Androgen deprivation therapy (ADT) remains the cornerstone of management of prostate cancer (PCa). Previous studies have shown that men undergoing ADT develop insulin resistance and diabetes, but the mechanisms behind ADT-induced metabolic abnormalities remain unclear. Objective: To evaluate the role of inflammatory cytokines and adipocyte protein-2 (aP2) in ADT-induced metabolic dysfunction. Participants and Interventions: This 6-month prospective cohort study enrolled nondiabetic men with PCa about to undergo ADT (ADT group) and a control group of nondiabetic men who had previously undergone prostatectomy for localized PCa and were in remission (non-ADT group); all participants had normal testosterone at study entry. Fasting blood samples were collected at baseline and at 6, 12, and 24 weeks after initiation of ADT and at the same intervals in the non-ADT group. Glucose, insulin, lipids, inflammatory cytokines, and C-reactive protein were measured. We also measured serum aP2, an adipocyte-secreted protein that promotes hepatic glucose production. Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated. Results: Seventy-three participants formed the analytical sample (33 ADT, 40 non-ADT). HOMA-IR increased in the ADT group (estimated change = 0.25; P = 0.05), but was unchanged in the non-ADT group (0.11; P = 0.342). Serum concentrations of inflammatory cytokines or aP2 did not change significantly. There was a treatment-associated increase in total (16 mg/dL; P < 0.001), high-density lipoprotein (8 mg/dL; P < 0.001), and low-density lipoprotein (7 mg/dL; P = 0.02) cholesterol. Conclusion:ADT-induced metabolic abnormalities were not associated with changes in circulating inflammatory cytokines or aP2 levels.
Authors: Thiago Gagliano-Jucá; Thomas G Travison; Paul L Nguyen; Philip W Kantoff; Mary-Ellen Taplin; Adam S Kibel; Robert Manley; Kathleen Hally; Richelle Bearup; Yusnie M Beleva; Grace Huang; Robert R Edwards; Shehzad Basaria Journal: J Pain Symptom Manage Date: 2017-09-21 Impact factor: 3.612
Authors: Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Chris J Malkin; Peter J Pugh; Richard D Jones; Dheeraj Kapoor; Kevin S Channer; T Hugh Jones Journal: J Clin Endocrinol Metab Date: 2004-07 Impact factor: 5.958
Authors: Paul L Nguyen; Petr Jarolim; Shehzad Basaria; Jonah P Zuflacht; Jessica Milian; Samoneh Kadivar; Powell L Graham; Andrew Hyatt; Philip W Kantoff; Joshua A Beckman Journal: J Am Heart Assoc Date: 2015-04-20 Impact factor: 5.501
Authors: Thiago Gagliano-Jucá; Karol M Pencina; Tomas Ganz; Thomas G Travison; Philip W Kantoff; Paul L Nguyen; Mary-Ellen Taplin; Adam S Kibel; Zhuoying Li; Grace Huang; Robert R Edwards; Elizabeta Nemeth; Shehzad Basaria Journal: Am J Physiol Endocrinol Metab Date: 2018-10-16 Impact factor: 4.310